NCT04721015: Study of Intravenous (IV ABBV-637) Alone or in Combination With IV Docetaxel to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R Solid Tumors)

NCT04721015
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Chemotherapy, Therapeutic antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Part 1
Exclusions: 
https://ClinicalTrials.gov/show/NCT04721015

Comments are closed.

Up ↑